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a b s t r a c t
Despite biochemical and genetic testing being the golden standards for identification of proximal urea
cycle disorders (UCDs), genotype-phenotype correlations are often unclear. Co-occurring partial defects
affecting more than one gene have not been demonstrated so far in proximal UCDs.
Here, we analyzed the mutational spectrum of 557 suspected proximal UCD individuals. We probed
oligomerizing forms of NAGS, CPS1 and OTC, and evaluated the surface exposure of residues mutated in
heterozygously affected individuals. BN-PAGE and gel-filtration chromatography were employed to
discover protein-protein interactions within recombinant enzymes.
From a total of 281 confirmed patients, only 15 were identified as “heterozygous-only” candidates (i.e.
single defective allele). Within these cases, the only missense variants to potentially qualify as dominant
negative triggers were CPS1 p.Gly401Arg and NAGS p.Thr181Ala and p.Tyr512Cys, as assessed by residue
oligomerization capacity and surface exposure. However, all three candidates seem to participate in
critical intramolecular functions, thus, unlikely to facilitate protein-protein interactions. This interpre-
tation is further supported by BN-PAGE and gel-filtration analyses revealing no multiprotein proximal
urea cycle complex formation.
Collectively, genetic analysis, structural considerations and in vitro experiments point against a
prominent role of dominant negative effects in human proximal UCDs.
© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
The proximal urea cycle disorders (UCDs) comprise deficiencies
of N-acetylglutamate synthase (NAGS, MIM 237310), carbamoyl
phosphate synthetase 1 (CPS1, MIM 237300), and ornithine trans-
carbamylase (OTC, OMIM 311250) that are located mainly in the
liver mitochondria. Besides these mitochondrial disorders, three
other conditions result from defects of cytosolic enzymes of the
urea cycle, namely argininosuccinate synthetase 1 deficiency
(ASS1D, OMIM 603470), argininosuccinate lyase deficiency (ASLD,
OMIM 608310) and arginase 1 deficiency (ARG1D, OMIM 608313).
In addition to the six enzymes of urea cycle, two transporters
shuttle intermediates between the mitochondria and cytoplasm;
the ornithine transporter (ORNT or SLC25A15) and citrin, also
known as ARALAR2 or SLC25A13 [1]. Defects in the two trans-
porters cause hyperornithinemia-hyperammonemia-homocitrullin
uria syndrome (OMIM 603861) and citrullinemia type II (OMIM
603859), respectively. Both conditions are accompanied by hyper-
ammonemia [2,3]. All UCDs are rare and inherited in an autosomal-
recessive manner, except for OTC deficiency (OTCD) which is X-
linked and the most common UCD, with an estimated incidence of
1:56,000 [4]. Most UCDs present in the neonatal period with en-
cephalopathy caused by accumulation of ammonia and other me-
tabolites, progressing into severe nausea and vomiting, seizures,
coma or even death [5e8]. Treatment of acute hyperammonemia
includes protein restriction and drugs that activate alternative
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ammonia disposal pathways, which should be administered as
soon as clinical suspicion arises andwhich should not be delayed by
metabolic investigations [9,10].
Following hyperammonemia detection, quantitative analyses of
plasma amino acids and urinary organic acids, including orotic acid
are performed to better define the most likely diagnosis. As a final
proof, genetic testing is nowadays recommended in most cases
[10].
Tight channeling of urea cycle intermediates in primary hepa-
tocytes and isolated mitochondria suggest that urea cycle enzymes
interact with each other [11,12]. This is supported by persistent low
blood concentration of citrulline in a patient with CPS1 deficiency
who received a liver transplant [13]; in this patient, urea cycle in-
termediates produced by the transplanted liver trapped citrulline
within the cycle and prevented its utilization in the renal biosyn-
thesis of arginine. Additionally, low abundance or absence of the
ASS protein in patients with type II citrullinemia due to citrin
deficiency strongly suggests that these two proteins interact [14].
Cytosolic urea cycle enzymes ASS and ASL also function in nitric
oxide signaling and form a multiprotein complex with nitric oxide
synthase (NOS) and the cationic amino acid transporter CAT-1
[15e18]. ASL is crucial for stability of the ASS-ASL-NOS-CAT-1
complex; this function of ASL is independent of its metabolic ac-
tivity in arginine biosynthesis. Therefore, defective and/or mis-
folded ASL protein can synergistically contribute to defects of NO
signaling via an ineffective NOS complex assembly [19]. A similar
protein complex destabilization occurs in the case of cobalamin A
(cblA)-type methylmalonic aciduria [20]. Missense mutations in
MMAA seem to disrupt the physiological interaction between
MMAAGTPase andmethylmalonyl-CoA mutase rather affecting the
intrinsic MMAA GTPase activity, which translates to disease cau-
sality in homozygous for the mutation individuals. Nonetheless,
only biallelic changes in the respective genes are known to lead to
human disease [20e22] and amino acid substitutions that lead to
defects in the case of the ASS-ASL-NOS-CAT-1 complex assembly
have not been described.
In contrast, heterozygous genetic defects can have a dominant
negative effect or occur in multiple genes of other metabolic
pathways. This latter synergistic heterozygosity can either arise due
to the cumulative effect of partial reduction of two or more mem-
bers of a pathway or due to instability of a multiprotein complex
[23]. For instance, the phenomenon of synergistic heterozygosity
was demonstrated in carnitine palmitoyltransferase 2 deficiency
(CPT2D, MIM 600649) and in very long-chain acyl-CoA dehydro-
genase deficiency (VLCAD, MIM 201475) [24], in sitosterolemia
(MIM 210250) [25], and recently also suggested for glycogen stor-
age disorders [23]. Similarly, dominant negative mutations have
been shown in a broad spectrum of conditions with highly different
etiologies including amino acidopathies, hematological disorders,
Alzheimer’s disease and cancer [26e29]. However, synergistic
heterozygosity or a dominant negative effect have not yet been
reported for proximal urea cycle disorders. Similarly, there is a lack
of data supporting the formation of a mitochondrial “urea cycle
multiprotein complex” although such complex would not be sur-
prising given the close interactions between the mitochondrial
urea cycle enzymes NAGS, CPS1 and OTC.
In order to search for evidence of dominant negative effects of
specific heterozygousmutations in the proximal urea cycle, we first
analyzed the mutational spectrum of 557 patients that were diag-
nosed in our laboratory over the past ten years. Combining the
findings of this clinical mutation analysis with protein structural
considerations, we conclude that dominant negative mutations are
likely not at play in any of the patients analyzed. In addition, we
performed in vitro evaluation of protein-protein interactions
among mitochondrial urea cycle enzymes, whereby we failed to




We present data on mutation analysis from patients with sus-
pected NAGS, CPS1, or OTC deficiency based on biochemical blood
(plasma ammonia and plasma or serum amino acid profiles) and/or
urine analysis (organic acid profile and/or orotic acid). Samples
were referred from48 different countries worldwide between 2008
and 2018. Depending on the request of the referring institution,
investigation of DNA, biopsies or blood samples was performed in
the laboratory of the Division of Metabolism at the University
Children’s Hospital Zurich. All samples were referred for clinical
testing of mutations, and patients and/or parents provided their
informed consent, which included the comprehensive analysis of
anonymized results.
2.2. Molecular genetic analysis
For CPS1 testing, analysis of mRNA by sequencing of cDNA was
performed whenever possible, followed by Sanger sequencing of
genomic DNA for confirmation of identified variants [30e32]. For
NAGS and OTC testing, exons were analyzed by either Sanger
sequencing [33,34] or next generation sequencing (NGS) as part of a
custom-made gene panel (covering coding exons and flanking
intronic regions) including analysis of copy number variations
(CNV). If no mutation was detected, further investigation was car-
ried out by sequencing NAGS and OTC cDNA [34e36], as well as
sequencing of enhancer and/or promotor regions of all three genes
[37e40] and/or OTC MLPA analysis using the SALSA MLPA KIT OTC
P079-A3 (MRC Holland).
Reference database entries used were the following: NAGS
GenBank AY116537.1 and GenBank NC_000017.10 and
NG_008106.1; CPS1 GenBank NM_001875.4 and GenBank
NC_000002.10 and NG_008285.1; OTC NM_000531.6 and GenBank
NC_000023.10 and NG_008471.1. Occurrence of replacements of
any of the amino acids in the interfaces of the NAGS tetramer and
CPS1 dimer in control cohorts was evaluated using gnomAD data-
base (https://gnomad.broadinstitute.org/) [41].
2.3. Human NAGS (hNAGS) structural modelling
Phyre2 web portal, a protein homology/analogy modelling
system, was used to predict secondary structure elements in
hNAGS, including part of the amino acid kinase (AAK) domain [42].
The method, which relies on homolog sequence detection (PSI-
BLAST) [43] and multiple sequence alignments of hidden Markov
models, enabled us to structurally align 432 residues (amino acids
96 to 527) covering 80% of hNAGS sequence. NAGS/K from Mar-
icaulis maris MCS10 (mmNAGS, PBD ID code: 3S7Y) was used as
template for this analysis [44]. Output model homology confidence
was 100% and sequence identity with the template reached 35%.
The stereo geometry of the model was good, with 80% and 15% of
the residues lying in the respective favourable or acceptable regions
of the Ramachandran plot [45]. Backbone phi/psi angle modelling
issues were observed for 20 residues. Model quality assessment
(MQA) was performed with ModFOLD 6, a hybrid model scoring
approach [46]. A global quality score of 0.59 (p¼ 1.77E-6) indicated
an accurately predicted hNAGS secondary structure
(Supplementary Fig. S1). Protein structures were visualized using
UCSF Chimera molecular modelling package [47].
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2.4. Residue solvent accessibility and oligomeric interface
predictions
To search for buried and/or exposed residues, we calculated the
solvent accessible areas or accessibilities (SAs) for all the involved
amino acids, using STRIDEweb server [48]. The crystal structures of
the recombinant human CPS1 (rhCPS1) (apo form PBD ID code:
5DOT), ligand-bound form PDB ID code: 5DOU), the N-acetylgluta-
mate transferase (NAT) domain of hNAGS (PDB ID code: 4K30) and
of the homology model of hNAGS (AAs: 96e527) were employed
[49,50]. The predicted SAs were divided by the maximum solvent
accessibility for every residue, derived from Gly-X-Gly extended
tripeptides and, thus, relative solvent accessibilities (RSAs) were
obtained [51e53]. A cut-off of 20% was chosen to distinguish be-
tween a buried or exposed state. Protein oligomerization potential
and interfacing surface residues were determined with the PISA
server (http://www.ebi.ac.uk/pdbe/pisa).
2.5. Expression of recombinant NAGS, CPS1 and OTC
For expression of recombinant hNAGS, a cDNA fragment (cDNA
derived from human liver tissue, Clontech, Palo Alto, CA) encoding
amino acids 49e534 was cloned into pNIC28-Bsa4 (GenBank™
accession EF198106) [54]. The plasmid was introduced into BL21
(DE3) R3-Rosetta E. coli cells, grown in TB medium with 50 mg/ml
kanamycin and expression was induced with 0.5 mM isopropyl-b-
D-thiogalactoside (IPTG) overnight at 18 C. Pelleted cells were
resuspended in the binding buffer (50 mM HEPES at pH 7.5, 10 mM
imidazole, 500 mM NaCl, 5% glycerol) containing protease in-
hibitors (Roche) and disrupted by three cycles of sonication using
Sonopuls UW2070 (Bandelin) for 5 min at 90% power setting at
4 C. Following clarification of the cell lysate by centrifugation, the
NAGS was purified by affinity (Ni-NTA, Qiagen) and size-exclusion
(Superdex 200, GE Healthcare) chromatography. Protein was
concentrated and stored in 10mMHEPES pH 7.5, 500mMNaCl, and
5% glycerol at 80 C.
Overexpression and purification of rhCPS1 was carried out as
previously described [55e57]. Briefly, protein expression and pro-
duction were mediated by the CPS1 cDNA-carrying bacmid, using
Bac-to-Bac® Baculovirus Expression System (Invitrogen) in Sf9 in-
sect cells. Purification was accomplished by N-terminal 6  His-tag
protein binding to a HisTrap HP 5 ml column incorporated in ӒKTA
FPLC system (GE Healthcare). CPS1 was eluted with a linear
gradient of imidazole-containing (20e500 mM) purification buffer
(50 mM glycyl-glycine pH 7.4, 500 mM NaCl, 1 mM DTT and 10%
glycerol). The resulting CPS1 fractions with pure CPS1 were pooled,
concentrated, and stored at 80 C.
The OTC was overexpressed in and purified from E. coli BL21
(DE3) bacterial strain with modifications of the previously
described protocol [58]. Briefly, following co-transformation with
OTCase (pET22b, T7 Lac expression) and chaperonins GroES and
GroEL (pGroESL) vector [58] transformed bacterial colonies were
grown with 0.1 mg/ml ampicillin and 0.035 mg/ml chloramphen-
icol at 37 C. Protein overexpression was induced with 0.01 mM
IPTG overnight at 25 C. Pelleted cells were resuspended in lysis
buffer (20 mM Tris-acetate pH 7.4, 0.1 M NaCl, 2 mM EDTA and
0.1 mM phenyl-methyl sulphonyl fluoride) and disrupted with
sonication. Protein precipitation steps with 0.22 and 0.26 g/ml
ammonium sulfate were followed by centrifugation, resuspension
in 10 mM triethanolamine buffer (pH 8) supplemented with 1 mM
EDTA and overnight dialysis at 4 C. Further protein purification
was conducted with a His-Trap Q 1 ml column (GE Healthcare);
eluted OTC was concentrated and stored in 20% v/v glycerol
at 80 C (kindly gifted by Dr. Vicente Rubio, Instituto de Bio-
medicina de Valencia, Spain).
2.6. Analysis of multiprotein complexes
Blue native-PAGE (BN-PAGE) was performed with the Native-
Page™Novex® Bis-Tris Gel Systems using Dark Blue Cathode Buffer
and 4e16% 15-well Bis-Tris precast Gels (Novex®) as described by
themanufacturer. Gels were run at 150V for 20e30min followed by
10min at 250 V or until no current was detectable (Powerpac™HC,
BioRad). Increasing amounts of the investigated proteins (1e7 mg)
and excess of their substrates and/or allosteric activators ornithine,
N-acetylglutamate (NAG), adenosine triphosphate (ATP) were
loaded and analyzed at two different temperatures (room tem-
perature and/or 0 C, Supplementary Table S1). Gel fixation and
destaining were performed according to manufacturer’s in-
structions using fixing (40% methanol, 10% acetic acid) and
destaining solutions (8% acetic acid).
Analytical gel filtration of CPS1 and OTC was performed on a
Superdex 200 HiLoad 10/30 column (GE Healthcare) pre-
equilibrated with filtration buffer (25 mM HEPES pH 7.5, 150 mM
NaCl and 5% glycerol). The column was calibrated using apoferritin
(443 kDa), alcohol dehydrogenase (150 kDa), bovine serum albu-
min (66 kDa) and carbonic anhydrase (29 kDa) (Sigma) as molec-
ular weight standards. Thereafter, 12 mM CPS1 and 25 mMOTC were
loaded on the column either separately or in combination, and the
absorbance at 280 nm was recorded. Column flowrate was 0.3 ml/
min and the measurement was terminated after a total flow-
through of 30 ml.
3. Results
3.1. Patient cohort and their molecular genetic background
The total number of unrelated patients in our cohort was 557
individuals. Specifically, 354 patients were referred with suspicion
of either CPS1 or NAGS (CPS1/NAGS) deficiency and 203 patients
with suspicion of OTC deficiency.
Of the 354 patients from the CPS1/NAGS deficient group, CPS1
deficiency could be confirmed in 120 cases (66 homozygous and 54
compound heterozygous) while NAGS deficiency was confirmed in
29 cases (27 homozygous and 2 compound heterozygous). Among
the confirmed cases, 7 CPS1 and 5 NAGS were novel mutations
(Table 1 and Supplementary Table S2). Disease causing sequence
variants were not found in the CPS1 and NAGS genes from 190
patients (Supplementary Table S2) while 15 patients had only one
heterozygous mutation (12 for CPS1 and 3 for NAGS; for details see
Fig. 1, Table 1). Of the initially 190 negative cases, 14 showed
pathogenic sequence variants in a different gene: 11 patients had
carbonic anhydrase VA (CAVA) deficiency, one patient demon-
strated lysinuric protein intolerance (LPI), one patient had a
defective TMEM70 gene, and one suffered from uridine mono-
phosphate synthase (UMPS) deficiency.
Of the 203 suspected OTCD patients, a disease-causingmutation
could be confirmed in 117 (64 hemizygous males and 53 hetero-
zygous females), whereas an OTC genetic lesion could not be
identified in 86 cases (Supplementary Table S2). Novel genetic le-
sions are reported in this study for 25 OTCD cases (Supplementary
Table S2). Three of the cases without OTC gene defects were sub-
sequently diagnosed with Canavan disease (ASPA gene defect),
myoadenylate deaminase (MAD) deficiency, and secondary CPS1
deficiency related to chemotherapy (Fig. 1; Diff. diagnosis - Other)
[59]. When analyzing OTCmutations, we discovered a difference in
maternal heterozygosity for the mutations among affected female
and male patients. In female patients, only 26% (5 out of 19) of the
mothers were carriers of the respective mutation, which contrasts
with affected males, where near 86% (30 out of 35) of the mothers
were carriers.
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Overall, our analysis could pinpoint a single defective allele in 15
out of 557 unrelated patients (12 CPS1D and 3 NAGSD; Table 1) and
no pathogenic sequence variants in the remaining two proximal
urea cycle genes. Such an outcome mitigates the concept of con-
current partial defects driving a synergistic mechanism of disease,
albeit these latter “heterozygous-only” variants were the basis for
the described structural considerations.
3.2. General structural considerations for CPS1 and NAGS proteins
To evaluate potential synergistic partial defects impacting on
the competency of the proximal UC enzymes to form amultiprotein
complex, we focused on identified suspected CPS1/NAGS deficient
cases with a single defective allele. Ten missense sequence variants
were found within the cohort of 12 patients with a single
Table 1
Patients with only one heterozygous mutation identified.
# Exon c. (DNA) p. (Protein) SIFT PolyPhen gnomAD Frequency Reference
NAGS




0.00004160 (10 alleles found) novel




0.000003997 (1 allele found) Sancho-Vaello
2016




0.00004242 (12 alleles found) Sancho-Vaello
2016
CPS1




no alleles found novel
1 5 c.528G>A
r.472_528del
p.(Val158_Lys176del) n.a. n.a. no alleles found novel
1 9 c.946A>T p.(Arg316*) n.a. n.a. no alleles found novel




no alleles found H€aberle 2011




0.0003261 (92 alleles found) Eeds 2006




no alleles found Funghini 2003




0.001907 (538 alleles found) H€aberle 2004




0.00002123 (6 alleles found) Diez 2014
1 25 c.3037_3039del p.(Val1013del) n.a. n.a. no alleles found Hu 2014




0.001519 (429 alleles found) Kurokawa 2007




0.000003978 (1 allele found) novel
a Together with c.1268 þ 11G>A (gnomAD frequency 0.001651, 460 alleles found) and c.1368C>G p.Ser456¼ (gnomAD frequency 0.001672, 440 alleles found) possible
effect on splicing.
b Together with c.1201G>C, p.(Gly401Arg) (gnomAD frequency 0.00002132, 6 alleles found).
Fig. 1. Complete patient cohort and their molecular genetic background. 117 OTCD, 132 CPS1D and 32 NAGSD of the suspected cases were confirmed using genetic and/or
biochemical testing in our facilities. Almost half of the total cases examined were negative for a genetic lesion impacting the proximal UC proteins and only 17 cases could be re-
assigned based on a differential diagnosis. Within the differential diagnosis group “Other” patients with Canavan disease (ASPA gene defect), myoadenylate deaminase (MAD)
deficiency, and secondary CPS1 deficiency related to chemotherapy are included. Abbreviations: CAVA, carbonic anhydrase VA; LPI, lysinuric protein intolerance; TMEM70,
transmembrane protein 70; UMPS, uridine monophosphate synthase.
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deleterious CPS1 allele including two individuals with the same
p.Lys875Glu substitution and one individual with two missense
lesions co-existing within the same allele (Table 1). Three patients
had sequence variants that either affected mRNA splicing or caused
reading frameshift and premature protein termination, and were
not examined further. Our analysis of protein structures aimed at
addressing the following two questions. First, whether the het-
erozygous missense sequence variants occur in key residues that
participate in the dimerization of CPS1 and tetramerization of NAGS
and thus, could exert a dominant negative effect. Second, the de-
gree of surface exposure for the mutated residues, which could
potentially lead to an interference with the hypothesized multi-
protein complex assembly. Several oligomeric interfaces were
generated by the PISA server for both CPS1 and the NAT domain of
NAGS and the top candidate, which exhibited maximal surface area
and highest solvation free energy gain, was selected.
3.3. Role of surface exposed CPS1 variants in dimerization and
protein-protein interactions
In a CPS1 dimer, 44 residues contribute to the interface between
the C-termini of the two enzyme monomers (Supplementary
Tables S3 and S4). Of those, 21 residues were found affected by
non-synonymous amino acid replacements with however minor
allele frequencies (MAF) <0.000005 for most of them
(Supplementary Table 5). Only exceptions are p.Gly1376Ser, a
known benign alteration [60], and p.Ile1215Val, which was found in
a single patient with CPS1D and has an MAF of 0.001595. The
Arg587 (mutated to Leu) maps in a highly disordered CPS1 poly-
peptide section that is missing from the apoCPS1 crystal (Fig. 2).
However, in the liganded CPS1 structure, Arg587 is located prox-
imal to the ATP-binding pocket of the bicarbonate phosphorylation
domain and facilitates interactions with bound ADP [49]. Hence, a
putative involvement into oligomerization ormultiprotein complex
formation of that part of the CPS1 chain is highly unlikely.
Next, we evaluated the percentage of accessible surface area,
presented as RSA. For the apo-form of CPS1, 876 of the 1352 resi-
dues were considered “buried”with RSA values below the 20% cut-
off (Fig. 2, Supplementary Table S6). The Gln810 and Ile1215 are
considered completely buriedwith less than 2.7% accessible surface
area. Three other residues, namely Gly401, Ala640 and Lys1444, are
moderately or highly exposed, which makes them potential me-
diators of protein-protein interactions during a UC complex as-
sembly. p.Gly401Arg co-exists with p.Ile937Asn within the same
allele of one patient, demonstrating an MAF of 0.00002132 and
0.00002123, respectively. Gly401 is the only residue that could
theoretically participate in a potential multiprotein complex given
its surface exposure (~52%) and accessible position in the crystal
structure. In contrast, Ile937 is completely buried both in the apo
and ligand-bound CPS1 (Supplementary Table S10). However, our
data indicate that p.Ile937Asn represents the disease-causing
variant for this missense pair since the residue maps within the
integrating domain of CPS1, a domain with essential structural and
functional intramolecular roles, and exhibits deleterious/probably
damaging scores in SIFT/PolyPhen predictive analysis (Table 1). A
residue surface exposure analysis for the ligand-bound form of CPS1
showed that Ala640 becomes buried (RSA ¼ 18.7%, Supplementary
Table S7) upon activation-oriented conformational rearrange-
ments, possibly “surface-protected” by a 20-amino acid flexible
linker that connects the glutaminase-like and bicarbonate phos-
phorylation moieties of the CPS1 ligand-bound conformation. The
Lys1444 is one of the key residues promoting the binding of the
allosteric activator N-acetyl-L-glutamate (NAG). Therefore, both
Ala640 and Lys1444 are unlikely to play a role as candidates for
Fig. 2. Surface exposure of apo-rhCPS1 residues. The affected amino acids in “heterozygous-only” CPS1D individuals are indicated on the surface representation of the crystal. The
backbone and side chain of the studied residues are shown as sticks. The Asp86, Ala640 and Ile937 are located at the back side of the protein structure, hence a 90 rotation was
applied for their depiction. The Arg587 is missing from the apo-crystal, thus its position is only shown in approximation. All structures (surfaces, residues, atoms) are color-coded
based on relative solvent accessible areas calculated for every amino acid using Gly-X-Gly extended tripeptide maximum solvent accessibilities as normalization factor. Red denotes
maximal and blue minimal surface exposure.
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stabilization of a NAGS-CPS1-OTC complex.
3.4. Role of surface exposed NAGS variants in tetramerization and
protein-protein interactions
In the NAGS tetramer, 21 residues are part of the interfaces and
hereby contribute to oligomerization (Supplementary Table S8).
Substitution of 10 interface residues were reported in gnomAD. As
with CPS1, all those replacements occur with MAF <0.00005
including the most prevalent, p.Tyr512Cys (Supplementary
Table 9). All three patients with NAGS deficiency and a single
deleterious allele displayed missense sequence variants, namely
p.Thr181Ala, p.Ser398Cys and p.Tyr512Cys (Table 1). Analysis of the
NAGS oligomer revealed that only Tyr512 could be a part of the
interface in the hNAGS tetramer; the Tyr512 residue has amoderate
RSA of 33.9% (Fig. 3a, Supplementary Tables S8 and S10). Indeed, p-
cation side-chain interactions occur between Tyr512 of subunit A
and Arg509 of subunit B, stabilizing the functional biological as-
sembly of the NAT domain [50]. The Ser398 residue is buried and
positioned in an alpha-helix near a cavity that corresponds to the
NAG binding site in bacterial the bi-functional NAGS/K homolog of
hNAGS [50]. The Thr181 analysis was based on an in-silicomodel of
hNAGS, which used as a homology template the crystal structure of
bi-functional NAGS/K from Maricaulis maris (mmNAGS/K)
(Supplementary Fig. S1). The residue is situated in a loose loop of
the AAK domain anti-diametrically of the catalytic site and is
moderately surface exposed (Fig. 3b, Supplementary Table S10).
Furthermore, Thr181 forms hydrogen bonds with Glu191 and hy-
drophobic interactions with Gln195 of the opposite alpha-helix,
possibly stabilizing the corresponding loop. In the mmNAGS/K,
where Thr181 is also conserved, the residue forms hydrogen bonds
with the nearby Gly184 and Asp183, likely supporting an analogous
function by stabilizing the turn of the loop in between two beta-
sheets. In turn, Glu180 and Asp183 are involved in electrostatic
interactions with three arginine residues (Arg110, Arg136 and
Arg151) of the neighbouring mmNAGS/K subunit contributing to
the tetrameric structure formation.
3.5. Absence of clear evidence for a proximal urea cycle
multiprotein complex
We used BN-PAGE to determine whether recombinant NAGS,
CPS1 and OTC can form a multiprotein complex. With this tech-
nique, we aimed at identifying a newly formed band close to the
combined molar weight (MW) of the hypothesized proximal UC
complex (approximately at 500 kDa, hereby assuming participation
of fully oligomerized proteins in a 1:1:1 ratio). The mobility of
native recombinant NAGS, CPS1 and OTC alone or mixed in
different combinations and ratios were assessed using BN-PAGE at
different temperatures, salt concentrations and in the presence or
absence of substrates (ATP, ornithine) and the allosteric activator
NAG (Supplementary Fig. S3). A band in the range of 500 kDa,
indicative of a NAGS-CPS1-OTC complex, was not observed. Instead,
bands corresponding to the trimeric OTC and tetrameric NAGSwere
present (Fig. 4a). A double band with mobility corresponding to
245 kDa was observed for CPS1 (Fig. 4a). We did observe high
molecular weight bands, characteristic of protein aggregation, in
every BN-PAGE gel we performed and irrespective of the conditions
used to perform electrophoresis.
Given the unclear nature and complexity of the results, we next
tried to simplify our approach. A favourable protein-protein inter-
action among the proximal UC enzymes would most likely occur
between CPS1 and OTC since both are committed to the first two
steps of the cycle and abundant in the liver mitochondria. To that
end, we employed size exclusion chromatography to identify a
potential co-eluting complex of CPS1 and OTC proteins. As
demonstrated in Fig. 4b, both OTC and CPS1 eluted as individual
peaks with elution volumes consistent with their calculated mo-
lecular weights; the CPS1 and OTC elution peaks served as a
fingerprint for each of the components. Hereby, CPS1 and OTC
mixtures had the same elution profile as when proteins were
analyzed individually, and a novel peak with elution volume cor-
responding to the combinedmolecular weight of CPS1 and OTCwas
not observed. CPS1 displayed a tendency to form high molecular
weight aggregates which eluted in the void volume of the column.
Collectively, analyses concerning the oligomerization potential,
the surface accessible areas and the in vitro protein-protein in-
teractions indicate that the residues affected by pathogenic
sequence variants found in suspected CPS1D or NAGSD individuals
with a single defective allele have either limited surface exposure
or are unlikely to exert dominant negative effects.
4. Discussion
4.1. Molecular genetic and functional considerations for UCDs
Molecular genetic analysis is the recommended method for
confirmation of a suspected UCD since it is minimally invasive, and
Fig. 3. Surface exposure of hNAGS variants. a Crystal structure of recombinant hNAGS (PDB ID code: 4K30, corresponding to the N-acetyltransferase domain, NAT). b Structural
model of hNAGS depicting Thr181 mapping on amino acid kinase (AAK) domain. Both the residue backbones (ribbon diagram) and the surface representations are color-coded
based on the relative solvent accessible areas calculated for every amino acid. Red denotes maximal and blue minimal surface exposure. For the NAGSD mutated residues
Tyr512, Ser398 and Thr181, the side chains are also shown.
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allows comprehensive family counselling and prenatal diagnostics
in future pregnancies [10]. While DNA-sequencing alone has only
about 85e90% sensitivity for OTC [61,62], using the currently
available panel of diagnostic tools can improve the overall sensi-
tivity and in fact results in higher detection rates, as in the case of
CPS1D [31]. Still, some patients may escape molecular genetic
analysis, for instance if regulatory domains are not assessed
[37,40,63], or analyses may turn out with only a single variant in
one of the alleles. In several (not only metabolic) disorders, patients
with heterozygous variants in one gene were found to carry
another variant in another gene whose product participates in the
same metabolic pathway, hence leading to synergistic effects that
progress to disease manifestation [23,25].
The proteins of the urea cycle are regulated as a unit by dietary
protein intake [64] and circadian rhythms [65], and may form a
multiprotein complex based on the tight channeling of urea cycle
intermediates [19]. A similar interaction between the mitochon-
drial enzymes of the urea cycle, namely NAGS, CPS1 and OTC, could
be hypothesized. In this study, we were interested in the effect of
the variants found in patients with a single defective NAGS or CPS1
allele on the structure of the respective enzymes. Further, we
wanted to study whether data derived from molecular genetic
analysis in our large patient cohort would even support the pres-
ence of synergistic action of heterozygous variants in more than
one gene. Finally, we performed preliminary experiments to sub-
stantiate in vitro the structural interaction of recombinant NAGS,
CPS1 and OTC proteins.
Fig. 4. Analysis of a multiprotein UC complex. a Blue native-PAGE of NAGS, CPS1 and OTC. Substrates ATP and ornithine were included in excess, except when apo-enzyme forms
were tested. The allosteric activator NAG was added in excess as indicated. b Molecular size exclusion chromatography. CPS1 (12 mM) and OTC (25 mM) elution profiles from
Superdex 200 HiLoad 10/30 column (GE Healthcare) were probed in individual runs and in combination. Molecular weights (MWs) of oligomeric forms were determined by
calibration standards (25 mM). Column flowrate was maintained constant at 0.3 ml/min. Eluted OTC fraction shows a visible peak between 29 and 66 kDa, close to the estimated
36 kDa of the mature OTC monomer. A shoulder peak is observed for eluted CPS1 fraction between 150 and 443 kDa, approximating the monomer (163 kDa) and dimer (326 kDa)
MWs. Abbreviations: ADH, alcohol dehydrogenase; BSA, bovine serum albumin.
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4.2. Data from patient cohort
Molecular genetic analysis in 557 patients with suspected de-
ficiencies of proximal UCDs yielded 120 confirmed CPS1 deficient
patients, 117 confirmed OTC deficient patients, and 29 confirmed
NAGS deficient patients. Within these cases, we were able to detect
25 OTC, 7 CPS1, and 5 NAGS novel mutations. Additionally, we
identified 15 patients (12 CPS1D and 3 NAGSD) each with a single
pathogenic variant on one of their NAGS or CPS1 alleles. We also
checked the literature for other patients with only a single variant
detected but found no comprehensive description, likely due to a
publication bias against including such “incomplete” genotypes in
their reports.
Amongst those patients that were initially negative in NAGS or
CPS1 testing, we found eight cases with variants in OTC. Similarly,
four CPS1 and one NAGS case were discovered in the initial OTCD
suspected group. This shows that not all UCD patients present with
a clear biochemical phenotype and indicates importance of NGS of
gene panels or even entire exomes or genomes rather than Sanger
sequencing of single genes.
It is noteworthy that among patients with CPS1 deficiency, there
was an even distribution of compound-heterozygous to homozy-
gous patients (54 and 66, respectively), while the majority of
NAGSD patients were homozygous (27, but only 2 patients
compound-heterozygous). This high rate of homozygosity among
patients with NAGSD was unexpected based on the existing mu-
tation updates [32,38]; the most likely explanation for this
discrepancy may be a higher proportion of consanguinity in this
cohort of families affected by NAGSD compared to the CPS1D
families. Unfortunately, due to the lack of respective clinical data,
we cannot verify this assumption.
Another interesting aspect of OTC mutation analysis in our
cohort was the finding that 86% of mothers were carriers of the OTC
variant in the case of male offspring, while only 26% of mothers
were carriers if their affected offspring was female. This phenom-
enon of different proportions of spontaneous mutations in female
andmale OTCD patients was reported before [66] and is most likely
explained by a higher rate of spontaneous mutations in male germ
cells.
4.3. Structural considerations
Analysis of 281 patients with confirmed proximal UCDs,
including the 15 patients that had a single defective allele, indicated
absence of heterozygous partial defects in multiple steps of the
cycle within our multinational cohort of cases. Next, we investi-
gated the residues affected by suspected heterozygous missense
mutations in CPS1 and NAGS. Human CPS1 is proposed to exist as
monomers or dimers in rapid equilibrium that energetically favours
the monomeric form. Simultaneously, we confirmed that less than
3% of the total number of residues appear to be involved in CPS1
oligomerization (apo form: 2.95%, ligand-bound form: 2.66%),
already proposed by others [49], and CPS1 and NAGS residues
constituting interface regions are rarely affected by replacements
according to gnomAD. Considering both the oligomerization ability
and the surface exposure, only Gly401 from CPS1 along with Tyr512
and Thr181 from NAGS whose replacements are known to be dis-
ease causing could potentially be involved in protein-protein in-
teractions. Gly401 is located within the glutaminase domain of
CPS1 polypeptide, whose precise function has yet to be defined.
Despite not having catalytic activity, the glutaminase domainmight
be important for enzyme folding and stabilization [49,67]. Never-
theless, the disease manifestation in this “heterozygous-only”
CPS1D individual seems to stem from the co-existing p.Ile937Asn
substitution, a deleterious variant that occurs within the more
central and functionally crucial integrating domain of CPS1 and
likely downplays additional negative effects arising from
p.Gly401Arg. Within hNAGS structure, Tyr512 seems to interact
with Arg509 of a nearby partner subunit, stabilizing the hNAT
domain [50]. In vitro biochemical analysis of patient-derived
p.Arg509Gln substitution demonstrated reduced affinity for both
NAGS substrates (glutamate and AcCoA) and compromised enzy-
matic activity, with the effects partially reverted upon arginine
supplementation [68]. In that case, an interaction between Tyr512
and Arg509 could be crucial for dynamic conformational changes
that would favour substrate association and NAGS activity
augmentation. The situation is less clear for Thr181 that maps
within the amino acid kinase domain (AAK) of NAGS, whose three-
dimensional structure is currently unknown. Thus, any performed
analysis is bound to rely on computational models or available
homologous crystal structures. Our NAGS model, which is based on
the mmNAGS/K from M. maris MCS10, conferred a moderate sur-
face exposure for Thr181, while interactions with the nearby resi-
dues Gly184 and Asp183 seem to facilitate loop stabilization.
Generally, the amino acid kinase (AAK) domain of mmNAGS/K, in a
similar fashion to glutaminase-like domain of CPS1, is enzymati-
cally non-functional, however, it enhances NAGS acetyltransferase
activity by 6- to 12-fold and is responsible for binding the allosteric
regulator L-arginine [69e72]. Moreover, the AAK domain possesses
a higher degree of flexibility than the NAT domain, which might be
the reason that determination of its structure is challenging. In
mmNAGS/K, spatial rearrangements of AAK towards the NAT
domain are observed upon arginine binding and appear to
contribute to the enzyme’s tetrameric complex stabilization
[44,73]. Therefore, the underlying yet not experimentally conclu-
sive significance of the kinase domain in hNAGS might be an
opposing factor towards intermolecular interactions existing
within the proximal urea cycle counterparts.
4.4. In vitro experiments
We further evaluated the ability of recombinant NAGS, CPS1 and
OTC to form a multiprotein complex, which could explain a syn-
ergistic heterozygosity scenario. No visible band in the MW range
that would be consistent with a multiprotein complex was present
for any of the tested combinations of NAGS, CPS1 and OTC with and
without substrates ornithine and ATP, as well as the allosteric
activator NAG. Further manipulation of the BN-PAGE conditions, i.e.
lowering the salt content and the temperature of the separation
run, neither alleviated the observed smearing of the gels nor
improved the quality of detection. Instead of a high molecular
weight band indicative of a NAGS-CPS1-OTC complex we observed
high molecular weight aggregates. Non-specific aggregation or
protein degradation, as observed for recombinant hNAGS and
mildly for recombinant hCPS1 (Supplementary Fig. S2) could
explain the lack of protein-protein interactions. Anionic coating of
proteins with Coomassie Blue G-250 dye added to the protein
mixture could lead to aberrant protein migration through the gel,
hence resulting in protein occlusion or misleading molecular
weight bands. Additionally, binding of Coomassie Blue dye to the
analyzed proteins could have interfered with the NAGS-CPS1-OTC
complex formation. We also used size exclusion chromatography
to test whether CPS1 and OTC can form a stable complex. No novel
peak corresponding to a CPS1-OTC complex was identified. The
sensitive nature of the CPS1 native structure could be a con-
founding factor for this effect, as it tended to form aggregates under
conditions employed in size exclusion chromatography. In vitro
techniques, such as pull-down assay or chemical crosslinking fol-
lowed by SDS-PAGE of the partner proteins could provide an
alternative experimental pipeline to capture potential transient
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protein-protein interactions. However, such techniques bring about
technical complications, i.e. presence of a protein selection tag, in
our case a 6  His-tag, which could hinder effective protein asso-
ciation. NAGS, CPS1 and OTC enzymes are supposed to function in
close proximity with one another though the exact spatial recog-
nition and interaction, if existing, might differ or only facilitate
physiologically at the cellular level. Nonetheless, with the experi-
mental setup employed and given its underlining limitations, a
multiprotein complex of proximal UC enzymes could not be
detected.
5. Conclusion
Taken together, findings from molecular genetic analysis of our
patient cohort, structural considerations, and in vitro experiments
into formation of a NAGS-CPS1-OTC complex with specific stoi-
chiometry do not provide evidence for either dominant negative
effects or potential multiprotein complex disruption during the
development of proximal UCDs. However, we cannot exclude that
cases of co-operative genetic lesions as well as transient protein-
protein interactions within the UC enzymes may occur at very
low frequency and should thus be considered in unsolved cases
with a strong suspicion of a proximal UCD.
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